2024-04-02 14:07:46 ET
Summary
- IMNM has acquired an anti-ROR1 antibody-drug conjugate, and ADC platform technology, from Zentalis Pharmaceuticals.
- IMNM has also acquired AL102 and AL101 from Ayala Pharmaceuticals. AL102 is already in a phase 3 study, with results expected in Q1'25.
- IMNM is also looking to acquire some antibody-related assets and materials from Atreca, subject to a stockholder vote.
- IMNM expects its cash to last into at least 2026.
I wrote about Immunome ( IMNM ) twice in 2023, including most recently in September when the company was merging with Morphimmune, and bringing on Clay Siegall as CEO. Siegall's appointment, the pipeline and the cash had me rating the company a strong buy. Since the merger, IMNM has engaged in several business development transactions to further build its pipeline and the technology available to it. This article takes a look at those developments, and why I now rate IMNM a buy rather than a strong buy....
Read the full article on Seeking Alpha
For further details see:
Immunome: An Oncology Powerhouse In The Making